Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Focal radiotherapy improves CAR T cell therapy targeting prostate cancer.

bioRxiv : the preprint server for biology·2026
Same author

Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.

The Lancet. Haematology·2026
Same author

AI-Driven Bone and Marrow Segmentation on FLT-PET/CT: Technical Multi-organ Validation in AML and HCT.

Research square·2026
Same author

Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026
Same author

Orchestrating segment anything models to accelerate segmentation annotation on agricultural image datasets.

Frontiers in artificial intelligence·2026
Same author

Current status and future potential of CD123-based targeted therapies for acute leukemia.

Expert opinion on biological therapy·2025

Related Experiment Video

Updated: May 3, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K

Targeted Irradiation and STAT3 Inhibition Reprogram the AML Microenvironment and Extend Survival: Toward

Srideshikan Sargur Madabushi, Jamison Brooks, Darren Zuro

    Biorxiv : the Preprint Server for Biology
    |June 4, 2025
    PubMed
    Summary

    Targeted marrow irradiation (TMI) combined with CSI-2, a STAT3 inhibitor, effectively clears acute myeloid leukemia (AML) and establishes lasting immune memory. This novel immunoradiotherapy strategy offers hope for treating high-burden or relapsed AML.

    More Related Videos

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
    09:44

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

    Published on: January 29, 2019

    7.4K
    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
    10:48

    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

    Published on: December 28, 2017

    9.1K

    Related Experiment Videos

    Last Updated: May 3, 2026

    Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
    09:04

    Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

    Published on: March 7, 2025

    1.8K
    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
    09:44

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

    Published on: January 29, 2019

    7.4K
    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
    10:48

    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

    Published on: December 28, 2017

    9.1K

    Area of Science:

    • Immunology
    • Oncology
    • Radiotherapy

    Background:

    • Acute myeloid leukemia (AML) relapses remain a significant clinical challenge despite therapeutic advances.
    • Total body irradiation (TBI) for AML, while effective, causes substantial organ toxicities and promotes immunosuppressive signaling via STAT3.
    • CSI-2, a STAT3 inhibitor, shows promise in enhancing anti-leukemic immunity but has limitations in high-disease burden scenarios.

    Purpose of the Study:

    • To investigate the synergistic potential of image-guided targeted marrow irradiation (TMI) and CSI-2 for improving leukemia clearance and inducing durable anti-leukemic immunity.
    • To assess if TMI can enhance the delivery and efficacy of CSI-2 by focusing radiation on leukemia sites while sparing healthy organs.

    Main Methods:

    • Mice with moderate-to-high bone marrow AML burden were treated with CSI-2 alone or in combination with TMI.
    • CSI-2 biodistribution was evaluated using fluorescent labeling and advanced microscopy techniques.
    • Therapeutic efficacy was assessed by monitoring survival, bone marrow composition via flow cytometry, and immunohistochemistry.

    Main Results:

    • TMI significantly enhanced CSI-2 uptake by leukemia and associated myeloid cells, improving vascular permeability.
    • The TMI/CSI-2 combination demonstrated superior reduction of high leukemia burden compared to CSI-2 monotherapy, achieving over 80% survival at 120 days.
    • This combination therapy led to increased infiltration of cytotoxic CD8+ and helper CD4+ T cells, and protection against AML rechallenge, indicating immune memory development.

    Conclusions:

    • The TMI/CSI-2 strategy represents a novel organ-sparing immunoradiotherapy with synergistic effects on leukemia clearance and long-term immunity.
    • This approach shows significant promise for treating high-burden or relapsed AML and warrants further investigation for clinical translation.